May 09, 2016 7:30am EDT Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO’s RAYALDEE®
Apr 28, 2016 4:17pm EDT OPKO to Announce First Quarter Operating and Financial Results on May 9, 2016
Apr 28, 2016 8:30am EDT OPKO Presents Additional Data on RAYALDEE® at National Kidney Foundation Spring Clinical Meetings 2016
Apr 25, 2016 11:48am EDT OPKO Announces Appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales
Mar 31, 2016 8:19am EDT OPKO Presents Additional Data on RAYALDEE® to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease
Mar 30, 2016 2:00am EDT OPKO Receives Complete Response Letter from FDA for RAYALDEE® New Drug Application
Mar 24, 2016 12:24pm EDT OPKO To Present 18-24 Month Clinical Data on its Long-acting Human Growth Hormone (hGH-CTP) from Open Label Extension (OLE) Phase 2 Pediatric Growth Hormone Deficiency Clinical Study in Oral Presentation at ENDO 2016